Pathophysiological Mechanisms in the Antiphospholipid Syndrome: B2GPI Regulation of FXI-FXIa

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/510130

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The major protein that the antibodies in the antiphospholipid syndrome (APS) bind is called Beta 2-GPI. Antibodies to Beta 2-GPI are associated with recurrent miscarriage, intrauterine growth retardation, clots and stroke. Treatment of patients with the APS are treated with medication that has significant side effects. The development of more targeted and effective therapies for the APS requires a greater understanding of how the antibodies cause their effects, which is addressed in this study.

Funded Activity Details

Start Date: 01-01-2008

End Date: 01-01-2010

Funding Scheme: NHMRC Project Grants

Funding Amount: $530,591.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Emergency medicine

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Animal models of thrombosis | Antiphospholipid antibodies | Antiphospholipid syndrome and thrombosis | Beta 2 glycoprotein I | FXI | FXIa | Recurrent miscarriage | Systemic lupus erythematosus

Related Links